GLOBAL WELLNESS STRATEGIES
GLOBAL WELLNESS STRATEGIES
Entering into the Chronic Pain Market with Psychedelics
Shanti has a targeted research pathway to clinical success, with strong proprietary protection under its already submitted patent providing a method for the treatment or prevention of pain.
Just like Cannabis investments of the early 2010s, smart investors are beginning to see the upside potential in investments into psychedelics and money has been flowing into start-ups like never before. GWS, through Shanti Therapeutics, is on the forefront of MDMA research in Australia.
Shanti plans to conduct clinical research on a fixed-dose combination drug with MDMA as the primary API potential adjuvant analgesic to reduce/ ablate the psychosocial component of pain.
Finding new drug solutions to the puzzle of chronic pain is novel and innovative. Shanti is an early mover with respect to entheogens (psychedelics) being used to modulate the psychosocial component of pain. Concurrent, with the trial being executed in Australia, a pre-IND application to the FDA will be conducted to help identify the best regulatory strategy to a new drug approval.
The hunt is on for the next miracle cure
The team at Shanti in Melbourne has finalized their clinical protocol and submitted it for ethics approval. Preparation has begun for an Australian FIH (First-in-Human) proof of concept trial. This trial will help identify the magnitude of the effect size of MDMA in treating pain which will guide the sample size determination for future pivotal clinical trials. MDMA has shown promise for PTSD, but the drug alone is unlikely to be a cure. The illegal substance, commonly known as Molly in the 1980’s was known as a college party drug for so long that many still do not believe MDMA paired with psychotherapy improves PTSD pathogenesis. Globally there are approx. 20 significantly funded companies (both listed and unlisted) conducting research and clinical trials into the potential applications (pain management, mental health, PTSD) of Ketamine, Psilocybin, DMT and MDMA and their respective derivatives / compounds.
KaleidoMyco is the story of people, process and production. Together world recognized mycologists and formulists, proprietary science driven IP and formulations, high bioavailability organic compounds, multiple delivery methods plus world-class extraction technologies make KaleidoMyco a leader in the mycology space.
KaleidoMyco is one of the world’s first companies combining hemp-extract (CBD), adaptogens and myco based ingredients to produce world-class wellness products. Their team of scientists are dedicated to driving ground-breaking innovations in the production and delivery of myco derived formulations. The first KaleidoMyco product is combining 50 milligrams of hemp-extract with functional mushrooms to launch a new one-shot wellness beverage utilizing its proprietary extraction techniques.
A proprietary blend of functional mushrooms and hemp extract delivered as a delicious effervescent added to water or your favorite drink.
A power packed shot of a proprietary blend of functional mushrooms and hemp extract
Sunshine State Tea is based in Boca Raton, Florida. Sunshine State Tea’s main product line is tasty infused hemp extract tea that has been tested to reveal zero percent THC. There are 8 varieties of tea; 4 caffeinated blends and 4 herbal decaffeinated ones. Each 8 tea bundle box has a diverse selection of loose tea flavors. Sunshine State production is manufactured in Washington State. The tea is certified and tested at a third party approved lab facility to authenticate and analyze the milligrams of hemp extract in the individual bags.
We have assembled a powerful team with diverse backgrounds to help us scale and create a global production and distribution company. The Biominerales Pharma team is positioning the company to be a meaningful player in the farming of Hemp Biomass, production of CBD Oil and CBD Isolate and consumer products manufactured under our brand, USA Hempire Farms.
We currently have hemp grow operations located in Colorado and Colombia, where Colombia features in-door and outdoor operations. Our ability to grow in both N. America in season and S. America all year long makes Biominerales Pharma a reliable supply chain partner for CBD oils and Isolates.
In addition to our growing operations we are building extraction lab facilities in Colorado and Colombia, all operations will be fully functional in 2020. All our facilities will meet the standards of CGMP.
Our consumer brand is marketed under USA Hempire Farms. The product line went through rigorous development and testing to assure we would deliver an effective and reliable product to our consumers. Each formula was developed by Pharmacists and is mixed and packaged in a CGMP lab in Miami, Florida.
launching cannabis and cannabidiol formulated products into Canada